Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
BIOCONNSE
Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 18% | 19% | 15% | 11% |
| -3% | -12% | -6% | -74% |
| 10% | 0% | 16% | -8% |
| 10% | 6% | 5% | 1% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
BIOCON
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 361.85 | ₹59052 Cr | 130.62 | 0.25 | 15.9 | ₹386 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | Dec 2013 | Sep 2013 | Jun 2013 | Mar 2013 | Dec 2012 | Sep 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹4389 Cr | ₹4336 Cr | ₹4517 Cr | ₹4173 Cr | ₹4296 Cr | ₹3942 Cr | ₹4417 Cr | ₹3821 Cr | ₹3590 Cr | ₹3433 Cr | ₹3917 Cr | ₹3954 Cr | ₹3462 Cr | ₹3423 Cr | ₹3774 Cr | ₹2941 Cr | ₹2320 Cr | ₹2140 Cr | ₹2409 Cr | ₹2174 Cr | ₹1840 Cr | ₹1761 Cr | ₹1842 Cr | ₹1857 Cr | ₹1750 Cr | ₹1694 Cr | ₹1558 Cr | ₹1717 Cr | ₹1567 Cr | ₹1459 Cr | ₹1529 Cr | ₹1541 Cr | ₹1321 Cr | ₹1124 Cr | ₹1170 Cr | ₹1058 Cr | ₹969 Cr | ₹934 Cr | ₹931 Cr | ₹1044 Cr | ₹954 Cr | ₹992 Cr | ₹957 Cr | ₹800 Cr | ₹789 Cr | ₹814 Cr | ₹838 Cr | ₹769 Cr | ₹758 Cr | ₹725 Cr | ₹729 Cr | ₹707 Cr | ₹741 Cr | ₹701 Cr | ₹637 Cr | ₹643 Cr | ₹629 Cr |
| ₹35 Cr | ₹55 Cr | ₹53 Cr | ₹117 Cr | ₹93 Cr | ₹80 Cr | ₹37 Cr | ₹35 Cr | ₹33 Cr | ₹1135 Cr | ₹49 Cr | ₹566 Cr | ₹158 Cr | ₹94 Cr | ₹155 Cr | ₹79 Cr | ₹65 Cr | ₹78 Cr | ₹67 Cr | ₹48 Cr | ₹105 Cr | ₹47 Cr | ₹205 Cr | ₹28 Cr | ₹16 Cr | ₹18 Cr | ₹63 Cr | ₹36 Cr | ₹38 Cr | ₹24 Cr | ₹28 Cr | ₹26 Cr | ₹54 Cr | ₹69 Cr | ₹68 Cr | ₹34 Cr | ₹51 Cr | ₹54 Cr | ₹43 Cr | ₹47 Cr | ₹38 Cr | ₹41 Cr | ₹16 Cr | ₹22 Cr | ₹23 Cr | ₹20 Cr | ₹17 Cr | ₹10 Cr | ₹15 Cr | ₹17 Cr | ₹17 Cr | ₹12 Cr | ₹12 Cr | ₹22 Cr | ₹12 Cr | ₹17 Cr | ₹13 Cr |
| ₹4423 Cr | ₹4391 Cr | ₹4569 Cr | ₹4290 Cr | ₹4389 Cr | ₹4022 Cr | ₹4454 Cr | ₹3856 Cr | ₹3623 Cr | ₹4567 Cr | ₹3966 Cr | ₹4519 Cr | ₹3620 Cr | ₹3516 Cr | ₹3929 Cr | ₹3020 Cr | ₹2384 Cr | ₹2217 Cr | ₹2476 Cr | ₹2223 Cr | ₹1945 Cr | ₹1808 Cr | ₹2048 Cr | ₹1885 Cr | ₹1765 Cr | ₹1712 Cr | ₹1621 Cr | ₹1753 Cr | ₹1606 Cr | ₹1483 Cr | ₹1557 Cr | ₹1566 Cr | ₹1375 Cr | ₹1193 Cr | ₹1237 Cr | ₹1092 Cr | ₹1019 Cr | ₹988 Cr | ₹974 Cr | ₹1092 Cr | ₹993 Cr | ₹1033 Cr | ₹973 Cr | ₹822 Cr | ₹811 Cr | ₹834 Cr | ₹855 Cr | ₹779 Cr | ₹773 Cr | ₹742 Cr | ₹746 Cr | ₹720 Cr | ₹753 Cr | ₹723 Cr | ₹649 Cr | ₹660 Cr | ₹642 Cr |
| ₹4122 Cr | ₹4036 Cr | ₹4010 Cr | ₹3855 Cr | ₹3933 Cr | ₹3631 Cr | ₹3775 Cr | ₹3495 Cr | ₹3325 Cr | ₹3218 Cr | ₹3408 Cr | ₹3441 Cr | ₹3110 Cr | ₹3066 Cr | ₹3140 Cr | ₹2598 Cr | ₹2080 Cr | ₹1958 Cr | ₹2029 Cr | ₹1892 Cr | ₹1596 Cr | ₹1566 Cr | ₹1591 Cr | ₹1644 Cr | ₹1536 Cr | ₹1447 Cr | ₹1391 Cr | ₹1417 Cr | ₹1296 Cr | ₹1146 Cr | ₹1246 Cr | ₹1277 Cr | ₹1094 Cr | ₹985 Cr | ₹1032 Cr | ₹934 Cr | ₹880 Cr | ₹840 Cr | ₹816 Cr | ₹839 Cr | ₹782 Cr | ₹795 Cr | ₹817 Cr | ₹679 Cr | ₹681 Cr | ₹665 Cr | ₹711 Cr | ₹666 Cr | ₹639 Cr | ₹603 Cr | ₹607 Cr | ₹583 Cr | ₹615 Cr | ₹597 Cr | ₹571 Cr | ₹539 Cr | ₹521 Cr |
| ₹865 Cr | ₹902 Cr | ₹1073 Cr | ₹951 Cr | ₹928 Cr | ₹846 Cr | ₹1115 Cr | ₹787 Cr | ₹718 Cr | ₹1755 Cr | ₹965 Cr | ₹1492 Cr | ₹900 Cr | ₹808 Cr | ₹1152 Cr | ₹723 Cr | ₹535 Cr | ₹477 Cr | ₹659 Cr | ₹537 Cr | ₹551 Cr | ₹437 Cr | ₹641 Cr | ₹428 Cr | ₹407 Cr | ₹432 Cr | ₹382 Cr | ₹480 Cr | ₹441 Cr | ₹462 Cr | ₹431 Cr | ₹406 Cr | ₹394 Cr | ₹307 Cr | ₹301 Cr | ₹256 Cr | ₹233 Cr | ₹246 Cr | ₹231 Cr | ₹324 Cr | ₹278 Cr | ₹304 Cr | ₹221 Cr | ₹206 Cr | ₹192 Cr | ₹228 Cr | ₹202 Cr | ₹170 Cr | ₹188 Cr | ₹191 Cr | ₹193 Cr | ₹188 Cr | ₹188 Cr | ₹175 Cr | ₹124 Cr | ₹167 Cr | ₹166 Cr |
| ₹240 Cr | ₹213 Cr | ₹232 Cr | ₹210 Cr | ₹272 Cr | ₹277 Cr | ₹212 Cr | ₹223 Cr | ₹226 Cr | ₹236 Cr | ₹227 Cr | ₹267 Cr | ₹248 Cr | ₹233 Cr | ₹249 Cr | ₹120 Cr | ₹30 Cr | ₹20 Cr | ₹11 Cr | ₹15 Cr | ₹23 Cr | ₹20 Cr | ₹34 Cr | ₹5 Cr | ₹7 Cr | ₹13 Cr | ₹17 Cr | ₹18 Cr | ₹14 Cr | ₹17 Cr | ₹16 Cr | ₹19 Cr | ₹19 Cr | ₹18 Cr | ₹17 Cr | ₹15 Cr | ₹14 Cr | ₹16 Cr | ₹5 Cr | ₹9 Cr | ₹7 Cr | ₹6 Cr | ₹21 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹0 | ₹5 Cr | ₹5 Cr | ₹58 L | ₹73 L | ₹26 L | ₹34 L | ₹38 L | ₹95 L | ₹3 Cr | ₹1 Cr |
| ₹55 Cr | ₹128 Cr | ₹248 Cr | -₹68 Cr | ₹171 Cr | ₹97 Cr | ₹487 Cr | ₹156 Cr | ₹98 Cr | ₹1146 Cr | ₹322 Cr | ₹832 Cr | ₹239 Cr | ₹217 Cr | ₹537 Cr | ₹30 Cr | ₹257 Cr | ₹240 Cr | ₹396 Cr | ₹316 Cr | ₹257 Cr | ₹222 Cr | ₹436 Cr | ₹237 Cr | ₹223 Cr | ₹252 Cr | ₹213 Cr | ₹318 Cr | ₹363 Cr | ₹321 Cr | ₹296 Cr | ₹277 Cr | ₹452 Cr | ₹190 Cr | ₹188 Cr | ₹144 Cr | ₹126 Cr | ₹131 Cr | ₹153 Cr | ₹244 Cr | ₹204 Cr | ₹232 Cr | ₹404 Cr | ₹141 Cr | ₹20 Cr | ₹165 Cr | ₹249 Cr | ₹109 Cr | ₹129 Cr | ₹138 Cr | ₹138 Cr | ₹137 Cr | ₹137 Cr | ₹126 Cr | ₹279 Cr | ₹118 Cr | ₹120 Cr |
| ₹57 Cr | ₹137 Cr | ₹199 Cr | -₹52 Cr | ₹133 Cr | ₹89 Cr | ₹459 Cr | ₹81 Cr | ₹27 Cr | ₹862 Cr | ₹226 Cr | ₹777 Cr | ₹197 Cr | ₹182 Cr | ₹455 Cr | ₹35 Cr | ₹110 Cr | ₹210 Cr | ₹337 Cr | ₹267 Cr | ₹210 Cr | ₹165 Cr | ₹366 Cr | ₹188 Cr | ₹200 Cr | ₹171 Cr | ₹159 Cr | ₹234 Cr | ₹263 Cr | ₹236 Cr | ₹255 Cr | ₹231 Cr | ₹379 Cr | ₹138 Cr | ₹148 Cr | ₹107 Cr | ₹83 Cr | ₹94 Cr | ₹143 Cr | ₹190 Cr | ₹162 Cr | ₹177 Cr | ₹349 Cr | ₹119 Cr | -₹8 Cr | ₹127 Cr | ₹217 Cr | ₹98 Cr | ₹107 Cr | ₹107 Cr | ₹119 Cr | ₹110 Cr | ₹105 Cr | ₹96 Cr | ₹251 Cr | ₹93 Cr | ₹90 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Revaluation reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 | Mar 2006 | Mar 2005 | Mar 2004 | Mar 2003 | Mar 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹811 Cr | ₹600 Cr | ₹600 Cr | ₹600 Cr | ₹600 Cr | ₹600 Cr | ₹600 Cr | ₹300 Cr | ₹300 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹100 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹2 Cr | ₹2 Cr |
| ₹514 Cr | ₹425 Cr | ₹320 Cr | ₹274 Cr | ₹204 Cr | ₹154 Cr | ₹109 Cr | ₹77 Cr | ₹69 Cr | ₹68 Cr | ₹61 Cr | ₹38 Cr | ₹121 Cr | ₹103 Cr | ₹93 Cr | ₹82 Cr | ₹62 Cr | ₹41 Cr | ₹36 Cr | ₹26 Cr | ₹11 Cr | ₹8 Cr | ₹5 Cr | ₹3 Cr | ₹0 |
| ₹32707 Cr | ₹20619 Cr | ₹18863 Cr | ₹16993 Cr | ₹7628 Cr | ₹6873 Cr | ₹5997 Cr | ₹5721 Cr | ₹4812 Cr | ₹4670 Cr | ₹3873 Cr | ₹3133 Cr | ₹2806 Cr | ₹2492 Cr | ₹2080 Cr | ₹1851 Cr | ₹1596 Cr | ₹1369 Cr | ₹1398 Cr | ₹993 Cr | ₹828 Cr | ₹682 Cr | ₹508 Cr | ₹129 Cr | ₹86 Cr |
| ₹32706 Cr | ₹20618 Cr | ₹18862 Cr | ₹16992 Cr | ₹7627 Cr | ₹6872 Cr | ₹5996 Cr | ₹5720 Cr | ₹4811 Cr | ₹4669 Cr | ₹3872 Cr | ₹3132 Cr | ₹2805 Cr | ₹2491 Cr | ₹2079 Cr | ₹1850 Cr | ₹1595 Cr | ₹1368 Cr | ₹1397 Cr | ₹991 Cr | ₹826 Cr | ₹681 Cr | ₹506 Cr | ₹127 Cr | ₹84 Cr |
| ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹90 L | ₹95 L | ₹95 L | ₹95 L | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹34032 Cr | ₹21644 Cr | ₹19784 Cr | ₹17867 Cr | ₹8433 Cr | ₹7627 Cr | ₹6706 Cr | ₹6098 Cr | ₹5181 Cr | ₹4838 Cr | ₹4034 Cr | ₹3271 Cr | ₹3027 Cr | ₹2695 Cr | ₹2272 Cr | ₹2033 Cr | ₹1758 Cr | ₹1511 Cr | ₹1484 Cr | ₹1069 Cr | ₹888 Cr | ₹741 Cr | ₹563 Cr | ₹134 Cr | ₹88 Cr |
| ₹2590 Cr | ₹6069 Cr | ₹5491 Cr | ₹4622 Cr | ₹1038 Cr | ₹881 Cr | ₹677 Cr | ₹609 Cr | ₹468 Cr | ₹376 Cr | ₹266 Cr | ₹172 Cr | ₹82 Cr | ₹65 Cr | ₹4 Cr | ₹38 Cr | ₹34 Cr | ₹25 Cr | -₹7 Cr | -₹80 L | ₹3 Cr | ₹88 L | ₹21,000 | ₹10,845 | ₹5,997 |
| ₹10476 Cr | ₹10503 Cr | ₹11268 Cr | ₹13692 Cr | ₹2574 Cr | ₹1492 Cr | ₹1221 Cr | ₹1524 Cr | ₹1787 Cr | ₹2104 Cr | ₹2061 Cr | ₹758 Cr | ₹580 Cr | ₹124 Cr | ₹9 Cr | ₹0 | ₹331 Cr | ₹396 Cr | ₹135 Cr | ₹74 Cr | ₹68 Cr | ₹49 Cr | ₹47 Cr | ₹58 Cr | ₹56 Cr |
| ₹270 Cr | ₹1903 Cr | ₹1665 Cr | ₹1598 Cr | ₹1424 Cr | ₹1469 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹11 Cr | ₹11 Cr | ₹26 Cr | ₹40 Cr | ₹61 Cr | ₹66 Cr | ₹182 Cr | ₹128 Cr | ₹120 Cr | ₹113 Cr | ₹37 Cr | ₹27 Cr | ₹17 Cr | ₹10 Cr | ₹11 Cr |
| -₹314 Cr | ₹100 Cr | ₹74 Cr | ₹81 Cr | -₹241 Cr | -₹275 Cr | -₹338 Cr | -₹325 Cr | -₹193 Cr | -₹198 Cr | -₹72 Cr | ₹42 Cr | ₹45 Cr | ₹41 Cr | -₹8 Cr | ₹50 Cr | ₹51 Cr | ₹47 Cr | ₹46 Cr | ₹45 Cr | ₹30 Cr | ₹23 Cr | ₹18 Cr | ₹14 Cr | ₹11 Cr |
| ₹1642 Cr | ₹3727 Cr | ₹1876 Cr | ₹5145 Cr | ₹2954 Cr | ₹2705 Cr | ₹1715 Cr | ₹855 Cr | ₹361 Cr | ₹358 Cr | ₹391 Cr | ₹552 Cr | ₹603 Cr | ₹457 Cr | ₹583 Cr | ₹339 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹330 Cr | ₹261 Cr | ₹238 Cr | ₹227 Cr | ₹92 Cr | ₹106 Cr | ₹86 Cr | ₹66 Cr | ₹49 Cr | ₹36 Cr | ₹30 Cr | ₹15 Cr | ₹8 Cr | ₹4 Cr | ₹1 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹12404 Cr | ₹16493 Cr | ₹15120 Cr | ₹20742 Cr | ₹6803 Cr | ₹5497 Cr | ₹2685 Cr | ₹2122 Cr | ₹2007 Cr | ₹2305 Cr | ₹2421 Cr | ₹1378 Cr | ₹1262 Cr | ₹666 Cr | ₹646 Cr | ₹456 Cr | ₹564 Cr | ₹571 Cr | ₹302 Cr | ₹232 Cr | ₹135 Cr | ₹100 Cr | ₹82 Cr | ₹83 Cr | ₹78 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹6772 Cr | ₹6549 Cr | ₹6272 Cr | ₹3842 Cr | ₹1609 Cr | ₹1514 Cr | ₹1325 Cr | ₹1198 Cr | ₹1005 Cr | ₹740 Cr | ₹610 Cr | ₹429 Cr | ₹347 Cr | ₹346 Cr | ₹348 Cr | ₹297 Cr | ₹231 Cr | ₹209 Cr | ₹172 Cr | ₹194 Cr | ₹193 Cr | ₹194 Cr | ₹103 Cr | ₹56 Cr | ₹36 Cr |
| ₹3059 Cr | ₹3966 Cr | ₹6481 Cr | ₹1815 Cr | ₹1031 Cr | ₹1840 Cr | ₹1784 Cr | ₹1375 Cr | ₹870 Cr | ₹698 Cr | ₹527 Cr | ₹706 Cr | ₹612 Cr | ₹313 Cr | ₹269 Cr | ₹376 Cr | ₹260 Cr | ₹148 Cr | ₹58 Cr | ₹39 Cr | ₹25 Cr | ₹18 Cr | ₹23 Cr | ₹14 Cr | ₹11 Cr |
| ₹3566 Cr | ₹3455 Cr | ₹2149 Cr | ₹2480 Cr | ₹896 Cr | ₹594 Cr | ₹668 Cr | ₹261 Cr | ₹130 Cr | ₹97 Cr | ₹395 Cr | ₹261 Cr | ₹244 Cr | ₹85 Cr | ₹187 Cr | ₹247 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹672 Cr | ₹365 Cr | ₹456 Cr | ₹374 Cr | ₹292 Cr | ₹262 Cr | ₹231 Cr | ₹204 Cr | ₹136 Cr | ₹143 Cr | ₹134 Cr | ₹158 Cr | ₹177 Cr | ₹247 Cr | ₹214 Cr | ₹142 Cr | ₹91 Cr | ₹82 Cr | ₹71 Cr | ₹43 Cr | ₹43 Cr | ₹37 Cr | ₹15 Cr | ₹3 Cr | ₹7 Cr |
| ₹14069 Cr | ₹14334 Cr | ₹15359 Cr | ₹8511 Cr | ₹3828 Cr | ₹4210 Cr | ₹4008 Cr | ₹3039 Cr | ₹2141 Cr | ₹1678 Cr | ₹1666 Cr | ₹1555 Cr | ₹1380 Cr | ₹990 Cr | ₹1018 Cr | ₹1062 Cr | ₹582 Cr | ₹438 Cr | ₹301 Cr | ₹275 Cr | ₹261 Cr | ₹249 Cr | ₹141 Cr | ₹73 Cr | ₹54 Cr |
| ₹63095 Cr | ₹58540 Cr | ₹55753 Cr | ₹51742 Cr | ₹20101 Cr | ₹18215 Cr | ₹14076 Cr | ₹11868 Cr | ₹9796 Cr | ₹9197 Cr | ₹8387 Cr | ₹6375 Cr | ₹5751 Cr | ₹4416 Cr | ₹3940 Cr | ₹3588 Cr | ₹2938 Cr | ₹2545 Cr | ₹2080 Cr | ₹1574 Cr | ₹1287 Cr | ₹1090 Cr | ₹786 Cr | ₹290 Cr | ₹219 Cr |
| ₹928 Cr | ₹1176 Cr | ₹1136 Cr | ₹948 Cr | ₹844 Cr | ₹700 Cr | ₹717 Cr | ₹811 Cr | ₹589 Cr | ₹1121 Cr | ₹591 Cr | ₹365 Cr | ₹315 Cr | ₹267 Cr | ₹227 Cr | ₹190 Cr | ₹154 Cr | ₹131 Cr | ₹101 Cr | ₹87 Cr | ₹83 Cr | ₹59 Cr | ₹25 Cr | ₹11 Cr | ₹11 Cr |
| ₹14825 Cr | ₹17756 Cr | ₹15730 Cr | ₹17771 Cr | ₹4904 Cr | ₹4359 Cr | ₹2625 Cr | ₹2407 Cr | ₹2264 Cr | ₹2303 Cr | ₹2478 Cr | ₹1117 Cr | ₹864 Cr | ₹267 Cr | ₹271 Cr | ₹334 Cr | ₹514 Cr | ₹524 Cr | ₹255 Cr | ₹187 Cr | ₹105 Cr | ₹76 Cr | ₹65 Cr | ₹69 Cr | ₹67 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹48079 Cr | ₹40804 Cr | ₹37930 Cr | ₹35321 Cr | ₹11233 Cr | ₹10221 Cr | ₹9147 Cr | ₹7095 Cr | ₹5874 Cr | ₹5436 Cr | ₹3404 Cr | ₹3034 Cr | ₹2702 Cr | ₹2481 Cr | ₹2066 Cr | ₹1966 Cr | ₹1837 Cr | ₹1582 Cr | ₹1182 Cr | ₹1066 Cr | ₹407 Cr | ₹330 Cr | ₹215 Cr | ₹174 Cr | ₹137 Cr |
| ₹11593 Cr | ₹8841 Cr | ₹7287 Cr | ₹5854 Cr | ₹4664 Cr | ₹3857 Cr | ₹3176 Cr | ₹2624 Cr | ₹2174 Cr | ₹1811 Cr | ₹1655 Cr | ₹1404 Cr | ₹1177 Cr | ₹971 Cr | ₹796 Cr | ₹650 Cr | ₹499 Cr | ₹370 Cr | ₹251 Cr | ₹171 Cr | ₹106 Cr | ₹76 Cr | ₹54 Cr | ₹38 Cr | ₹24 Cr |
| ₹36486 Cr | ₹31963 Cr | ₹30644 Cr | ₹29468 Cr | ₹6569 Cr | ₹6364 Cr | ₹5971 Cr | ₹4471 Cr | ₹3700 Cr | ₹3625 Cr | ₹1748 Cr | ₹1630 Cr | ₹1525 Cr | ₹1510 Cr | ₹1271 Cr | ₹1316 Cr | ₹1338 Cr | ₹1212 Cr | ₹931 Cr | ₹895 Cr | ₹301 Cr | ₹254 Cr | ₹161 Cr | ₹136 Cr | ₹113 Cr |
| ₹4613 Cr | ₹4102 Cr | ₹3985 Cr | ₹2588 Cr | ₹3420 Cr | ₹2254 Cr | ₹1577 Cr | ₹1287 Cr | ₹779 Cr | ₹533 Cr | ₹2060 Cr | ₹1494 Cr | ₹1083 Cr | ₹205 Cr | ₹286 Cr | ₹167 Cr | ₹76 Cr | ₹172 Cr | ₹138 Cr | ₹71 Cr | ₹526 Cr | ₹325 Cr | ₹59 Cr | ₹8 Cr | ₹5 Cr |
| ₹1089 Cr | ₹680 Cr | ₹684 Cr | ₹742 Cr | ₹370 Cr | ₹743 Cr | ₹109 Cr | ₹183 Cr | ₹64 Cr | ₹188 Cr | ₹26 Cr | ₹0 | ₹65 Cr | ₹65 Cr | ₹64 Cr | ₹61 Cr | ₹47 Cr | ₹39 Cr | ₹32 Cr | ₹18 Cr | ₹52 Cr | ₹18 Cr | ₹13,000 | ₹1,202 | ₹7,182 |
| ₹1089 Cr | ₹680 Cr | ₹684 Cr | ₹742 Cr | ₹370 Cr | ₹743 Cr | ₹109 Cr | ₹183 Cr | ₹64 Cr | ₹188 Cr | ₹26 Cr | ₹0 | ₹65 Cr | ₹65 Cr | ₹64 Cr | ₹61 Cr | ₹47 Cr | ₹39 Cr | ₹32 Cr | ₹18 Cr | ₹52 Cr | ₹18 Cr | ₹13,000 | ₹1,202 | ₹7,182 |
| ₹974 Cr | ₹871 Cr | ₹893 Cr | ₹683 Cr | ₹484 Cr | ₹436 Cr | ₹402 Cr | ₹336 Cr | ₹437 Cr | ₹320 Cr | ₹289 Cr | ₹337 Cr | ₹252 Cr | ₹242 Cr | ₹182 Cr | ₹140 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹380 Cr | ₹231 Cr | ₹361 Cr | ₹1198 Cr | ₹185 Cr | ₹271 Cr | ₹73 Cr | ₹91 Cr | ₹144 Cr | ₹176 Cr | ₹112 Cr | ₹170 Cr | ₹65 Cr | ₹47 Cr | ₹32 Cr | ₹60 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹45915 Cr | ₹42253 Cr | ₹40574 Cr | ₹39408 Cr | ₹11718 Cr | ₹10614 Cr | ₹8751 Cr | ₹6979 Cr | ₹5648 Cr | ₹5149 Cr | ₹4416 Cr | ₹3813 Cr | ₹3112 Cr | ₹2176 Cr | ₹1939 Cr | ₹1779 Cr | ₹1461 Cr | ₹1423 Cr | ₹1101 Cr | ₹983 Cr | ₹879 Cr | ₹596 Cr | ₹219 Cr | ₹144 Cr | ₹118 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹690 Cr | ₹447 Cr | ₹316 Cr | ₹1327 Cr | ₹1218 Cr | ₹1213 Cr | ₹858 Cr | ₹829 Cr | ₹611 Cr | ₹1065 Cr | ₹875 Cr | ₹230 Cr | ₹700 Cr | ₹522 Cr | ₹492 Cr | ₹400 Cr | ₹383 Cr | ₹329 Cr | ₹443 Cr | ₹61 Cr | ₹49 Cr | ₹217 Cr | ₹22 Cr | ₹5 Cr | ₹0 |
| ₹6086 Cr | ₹4931 Cr | ₹4944 Cr | ₹4244 Cr | ₹2298 Cr | ₹1867 Cr | ₹1436 Cr | ₹1032 Cr | ₹723 Cr | ₹635 Cr | ₹542 Cr | ₹453 Cr | ₹377 Cr | ₹398 Cr | ₹378 Cr | ₹414 Cr | ₹372 Cr | ₹319 Cr | ₹179 Cr | ₹161 Cr | ₹110 Cr | ₹74 Cr | ₹86 Cr | ₹48 Cr | ₹24 Cr |
| ₹5987 Cr | ₹5488 Cr | ₹6231 Cr | ₹3573 Cr | ₹2058 Cr | ₹1517 Cr | ₹1224 Cr | ₹1292 Cr | ₹1064 Cr | ₹883 Cr | ₹715 Cr | ₹771 Cr | ₹600 Cr | ₹510 Cr | ₹492 Cr | ₹496 Cr | ₹446 Cr | ₹367 Cr | ₹259 Cr | ₹307 Cr | ₹224 Cr | ₹182 Cr | ₹119 Cr | ₹75 Cr | ₹65 Cr |
| ₹3194 Cr | ₹4120 Cr | ₹2259 Cr | ₹2400 Cr | ₹1748 Cr | ₹2049 Cr | ₹999 Cr | ₹1057 Cr | ₹1323 Cr | ₹1044 Cr | ₹1539 Cr | ₹938 Cr | ₹804 Cr | ₹673 Cr | ₹523 Cr | ₹442 Cr | ₹140 Cr | ₹12 Cr | ₹10 Cr | ₹9 Cr | ₹2 Cr | ₹3 Cr | ₹318 Cr | ₹3 Cr | ₹2 Cr |
| ₹419 Cr | ₹383 Cr | ₹334 Cr | ₹334 Cr | ₹660 Cr | ₹661 Cr | ₹459 Cr | ₹376 Cr | ₹318 Cr | ₹372 Cr | ₹217 Cr | ₹79 Cr | ₹51 Cr | ₹45 Cr | ₹48 Cr | ₹20 Cr | ₹16 Cr | ₹62 L | ₹5 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹0 | ₹0 |
| ₹805 Cr | ₹917 Cr | ₹1096 Cr | ₹456 Cr | ₹401 Cr | ₹293 Cr | ₹350 Cr | ₹302 Cr | ₹110 Cr | ₹48 Cr | ₹84 Cr | ₹92 Cr | ₹107 Cr | ₹92 Cr | ₹69 Cr | ₹39 Cr | ₹120 Cr | ₹95 Cr | ₹83 Cr | ₹52 Cr | ₹22 Cr | ₹14 Cr | ₹21 Cr | ₹15 Cr | ₹11 Cr |
| ₹17180 Cr | ₹16286 Cr | ₹15179 Cr | ₹12334 Cr | ₹8382 Cr | ₹7600 Cr | ₹5325 Cr | ₹4889 Cr | ₹4149 Cr | ₹4048 Cr | ₹3971 Cr | ₹2563 Cr | ₹2639 Cr | ₹2240 Cr | ₹2002 Cr | ₹1809 Cr | ₹1477 Cr | ₹1122 Cr | ₹979 Cr | ₹591 Cr | ₹409 Cr | ₹494 Cr | ₹567 Cr | ₹146 Cr | ₹101 Cr |
| ₹3111 Cr | ₹1952 Cr | -₹180 Cr | ₹3823 Cr | ₹4554 Cr | ₹3390 Cr | ₹1317 Cr | ₹1850 Cr | ₹2007 Cr | ₹2369 Cr | ₹2305 Cr | ₹1008 Cr | ₹1259 Cr | ₹1250 Cr | ₹984 Cr | ₹747 Cr | ₹895 Cr | ₹683 Cr | ₹677 Cr | ₹316 Cr | ₹148 Cr | ₹245 Cr | ₹426 Cr | ₹73 Cr | ₹48 Cr |
| ₹63095 Cr | ₹58540 Cr | ₹55753 Cr | ₹51742 Cr | ₹20101 Cr | ₹18215 Cr | ₹14076 Cr | ₹11868 Cr | ₹9796 Cr | ₹9197 Cr | ₹8387 Cr | ₹6375 Cr | ₹5751 Cr | ₹4416 Cr | ₹3940 Cr | ₹3588 Cr | ₹2938 Cr | ₹2545 Cr | ₹2080 Cr | ₹1574 Cr | ₹1287 Cr | ₹1090 Cr | ₹786 Cr | ₹290 Cr | ₹219 Cr |
| ₹207 | ₹177 | ₹162 | ₹147 | ₹69 | ₹62 | ₹55 | ₹100 | ₹85 | ₹238 | ₹199 | ₹162 | ₹145 | ₹130 | ₹109 | ₹97 | ₹85 | ₹73 | ₹145 | ₹104 | ₹88 | ₹73 | ₹56 | ₹701 | ₹468 |
| ₹207 | ₹177 | ₹162 | ₹147 | ₹69 | ₹62 | ₹55 | ₹50 | ₹43 | ₹40 | ₹33 | ₹27 | ₹24 | ₹22 | ₹18 | ₹16 | ₹14 | ₹12 | ₹12 | ₹9 | ₹7 | ₹6 | ₹5 | ₹1 | ₹1 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Translation adjustment on reserves / op cash balalces frgn subsidiaries
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 | Mar 2006 | Mar 2005 | Mar 2004 | Mar 2003 | Mar 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹448 Cr | ₹1887 Cr | ₹1525 Cr | ₹897 Cr | ₹983 Cr | ₹1068 Cr | ₹1186 Cr | ₹1215 Cr | ₹610 Cr | ₹850 Cr | ₹751 Cr | ₹624 Cr | ₹538 Cr | ₹610 Cr | ₹395 Cr | ₹447 Cr | ₹351 Cr | ₹104 Cr | ₹539 Cr | ₹211 Cr | ₹203 Cr | ₹215 Cr | ₹162 Cr | ₹55 Cr | ₹26 Cr |
| ₹2921 Cr | ₹1711 Cr | ₹2356 Cr | ₹1685 Cr | ₹1245 Cr | ₹710 Cr | ₹606 Cr | ₹260 Cr | ₹356 Cr | ₹204 Cr | ₹42 Cr | ₹74 Cr | ₹134 Cr | ₹147 Cr | ₹145 Cr | ₹164 Cr | ₹160 Cr | ₹136 Cr | -₹214 Cr | ₹82 Cr | ₹28 Cr | ₹13 Cr | ₹18 Cr | ₹22 Cr | ₹13 Cr |
| -₹1132 Cr | ₹923 Cr | -₹635 Cr | -₹501 Cr | -₹790 Cr | -₹424 Cr | -₹165 Cr | -₹29 Cr | -₹107 Cr | -₹211 Cr | -₹176 Cr | -₹354 Cr | ₹38 Cr | -₹192 Cr | ₹98 Cr | ₹269 Cr | -₹35 Cr | -₹128 Cr | ₹17 Cr | -₹125 Cr | -₹126 Cr | -₹43 Cr | -₹31 Cr | -₹18 Cr | -₹20 Cr |
| ₹2237 Cr | ₹4521 Cr | ₹3246 Cr | ₹2081 Cr | ₹1439 Cr | ₹1354 Cr | ₹1627 Cr | ₹1446 Cr | ₹859 Cr | ₹843 Cr | ₹617 Cr | ₹344 Cr | ₹709 Cr | ₹565 Cr | ₹638 Cr | ₹880 Cr | ₹477 Cr | ₹112 Cr | ₹342 Cr | ₹168 Cr | ₹104 Cr | ₹184 Cr | ₹148 Cr | ₹59 Cr | ₹19 Cr |
| ₹1994 Cr | ₹4061 Cr | ₹2954 Cr | ₹1853 Cr | ₹1177 Cr | ₹1160 Cr | ₹1283 Cr | ₹1155 Cr | ₹662 Cr | ₹640 Cr | ₹371 Cr | ₹211 Cr | ₹561 Cr | ₹471 Cr | ₹564 Cr | ₹799 Cr | ₹444 Cr | ₹95 Cr | ₹318 Cr | ₹155 Cr | ₹81 Cr | ₹172 Cr | ₹129 Cr | ₹49 Cr | ₹15 Cr |
| -₹2082 Cr | -₹234 Cr | -₹1005 Cr | -₹14282 Cr | -₹1699 Cr | -₹3625 Cr | -₹1559 Cr | -₹714 Cr | -₹684 Cr | -₹499 Cr | -₹1142 Cr | -₹509 Cr | -₹938 Cr | -₹376 Cr | -₹360 Cr | -₹315 Cr | -₹226 Cr | -₹232 Cr | -₹340 Cr | -₹191 Cr | -₹89 Cr | -₹485 Cr | -₹108 Cr | -₹45 Cr | -₹41 Cr |
| -₹924 Cr | -₹1854 Cr | -₹2333 Cr | ₹13049 Cr | ₹242 Cr | ₹2564 Cr | ₹388 Cr | -₹242 Cr | -₹240 Cr | -₹178 Cr | ₹1068 Cr | ₹186 Cr | ₹426 Cr | -₹9 Cr | -₹186 Cr | -₹275 Cr | -₹85 Cr | ₹137 Cr | ₹23 Cr | ₹43 Cr | ₹5 Cr | -₹2 Cr | ₹294 Cr | -₹3 Cr | ₹24 Cr |
| -₹1012 Cr | ₹1973 Cr | -₹383 Cr | ₹619 Cr | -₹280 Cr | ₹99 Cr | ₹112 Cr | ₹199 Cr | -₹262 Cr | -₹36 Cr | ₹297 Cr | -₹112 Cr | ₹49 Cr | ₹87 Cr | ₹18 Cr | ₹209 Cr | ₹133 Cr | -₹16 L | ₹99 L | ₹7 Cr | -₹3 Cr | -₹315 Cr | ₹315 Cr | ₹77 L | -₹2 Cr |
| ₹2924 Cr | ₹920 Cr | ₹1300 Cr | ₹654 Cr | ₹897 Cr | ₹825 Cr | ₹659 Cr | ₹449 Cr | ₹710 Cr | ₹758 Cr | ₹458 Cr | ₹557 Cr | ₹474 Cr | ₹369 Cr | ₹359 Cr | ₹140 Cr | ₹12 Cr | ₹10 Cr | ₹9 Cr | ₹2 Cr | ₹3 Cr | ₹318 Cr | ₹3 Cr | ₹2 Cr | ₹1 L |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹34 Cr | -₹34 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹11 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 Cr | ₹45 L | ₹0 | ₹0 | ₹4 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹38 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹4 Cr | ₹30 Cr | ₹18 Cr | ₹26 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹199 Cr | ₹31 Cr | ₹3 Cr | ₹22 Cr | ₹3 Cr | ₹7 Cr | ₹54 Cr | ₹11 Cr | ₹40 L | -₹11 Cr | ₹4 Cr | ₹2 Cr | ₹5 Cr | ₹50 L | ₹4 Cr | ₹10 Cr | -₹1 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2112 Cr | ₹2924 Cr | ₹920 Cr | ₹1295 Cr | ₹654 Cr | ₹897 Cr | ₹825 Cr | ₹659 Cr | ₹449 Cr | ₹710 Cr | ₹758 Cr | ₹463 Cr | ₹557 Cr | ₹474 Cr | ₹369 Cr | ₹359 Cr | ₹143 Cr | ₹12 Cr | ₹10 Cr | ₹9 Cr | ₹2 Cr | ₹3 Cr | ₹318 Cr | ₹3 Cr | ₹2 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 2 out of 9 oscillators
RSI
54.12Neutral
STOCH %K
71.30Neutral
MACD Level(12,26)
1.52Buy
Ultimate Oscillator
48.12Sell
Aroon Oscillator
-58.00Sell
BOP
0.31Buy
CCI
49.23Neutral
Williams %R
-28.70Neutral
Momentum
9.70Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 4 out of 9 moving averages
EMA 9
362.63Buy
SMA 9
364.79Sell
EMA 21
359.86Buy
SMA 21
355.18Buy
EMA 50
366.73Sell
SMA 50
363.05Buy
EMA 200
383.17Sell
SMA 200
389.94Sell
WMA 20
361.54Buy
Pivot
Pivot
Classic
Resistance 5
390.12
Resistance 4
383.32
Resistance 3
376.52
Resistance 2
369.72
Resistance 1
366.68
Pivot
362.92
Support 1
359.88
Support 2
356.12
Support 3
349.32
Support 4
342.52
Support 5
335.72
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 44.68% | 44.68% | 44.91% | 54.45% | 54.45% | 54.45% |
| 8.64% | 8.14% | 7.52% | 7.39% | 6.61% | 6.04% |
| 7.14% | 7.86% | 7.48% | 7.92% | 7.93% | 7.59% |
| 22.08% | 15.47% | 16.53% | 13.75% | 14.13% | 15.24% |
| 17.46% | 23.85% | 23.56% | 16.49% | 16.88% | 16.68% |
Bulk & block deals
Name
Kotak Mahindra Matual Fund
Societe Generale
Aditya Birla Sun Life Mutual Fund
Whiteoak Capital Mutual Fund
Sbi Mutual Fund
Citigroup Global Markets Singapore Pte Limited
Bajaj Life Insurance Limited
Icici Prudential Life Insurance Company Limited
Bnp Paribas Arbitrage
Activ Pine Llp
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 09 Sep 2026 | Purchase | 49.16 Cr | ₹385 | 12.77 L | Block | 0.078358 | BSE |
| 09 Sep 2026 | Purchase | 25.03 Cr | ₹385 | 6.50 L | Block | 0.039885 | BSE |
| 09 Sep 2026 | Purchase | 49.16 Cr | ₹385 | 12.77 L | Block | 0.078358 | BSE |
| 09 Sep 2026 | Purchase | 25.03 Cr | ₹385 | 6.50 L | Block | 0.039885 | BSE |
| 09 Sep 2026 | Purchase | 54.82 Cr | ₹385 | 14.24 L | Block | 0.087378 | BSE |
| 09 Sep 2026 | Purchase | 25.03 Cr | ₹385 | 6.50 L | Block | 0.039885 | BSE |
| 09 Sep 2026 | Purchase | 25.03 Cr | ₹385 | 6.50 L | Block | 0.039885 | BSE |
| 09 Sep 2026 | Purchase | 25.03 Cr | ₹385 | 6.50 L | Block | 0.039885 | BSE |
| 09 Sep 2026 | Purchase | 25.03 Cr | ₹385 | 6.50 L | Block | 0.039885 | BSE |
| 09 Sep 2026 | Sell | 638.38 Cr | ₹385 | 1.66 Cr | Bulk | 1.017441 | BSE |
Insider trading & SAST
Client name
Mylan Inc.
Mylan Inc
Sbi Mutual Fund
Sbi Mutual Fund
Yamini Mazumdar
Yamini Mazumdar
Yamini Mazumdar
Yamani Mazumdar
Dev Mazumdar
Life Insurance Corporation Of India
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | Other | Disposal | 5.64 | — | 0 | — | 9.20 Cr | 14 Jul 2026 | Market | — | SAST | 29(2) | — |
| 09 Feb 2026 | Other | Acquisition | 6.88 | 6.88 | 0 | — | 9.20 Cr | 05 Jan 2026 | Pref. Allotment | 9,19,67,019 | SAST | 29(1) | — |
| 09 Feb 2026 | — | Acquisition | 2.21 | 7.03 | 0 | — | 3.35 Cr | 16 Jan 2026 | Market | 11,40,78,126 | SAST | 29(2) | — |
| 13 Nov 2025 | — | Acquisition | 0.02 | 5 | 0 | — | 3.70 L | 11 Nov 2025 | Market | 6,68,65,887 | SAST | 29(1) | — |
| 24 Dec 2024 | Promoter | Pledge | 0 | — | 0 | — | 10 K | 22 Aug 2017 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | 0 | — | 0 | — | 20 K | 21 Aug 2017 | Release | 10,000 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | 0 | — | 0 | — | 40 K | 09 Aug 2017 | Release | 30,000 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 40 K | 02 Jan 2015 | Creation | 50,000 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 20 K | 18 Jul 2014 | Release | 0 | SAST | Reg31 | — |
| 01 Oct 2024 | Other | Acquisition | 0.04 | 5.02 | 0 | — | 5 L | 13 Sep 2024 | Market | 6,03,14,429 | SAST | 29(1) | — |
Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics,
Corporate Actions
Date
Type
Details
Company details
Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Biocon Share Price
364.40+0.00 (+0.21%)
-8.18% past 1 Year
News
1 of 20
Stock NewsBIOCON18 Nov 2026
The company’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the EMA’s new tailored clinical approach
Biocon gets marketing authorization for Pebrilzo in EU
Stock NewsBIOCON18 Nov 2026
The company’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the EMA’s new tailored clinical approach
Biocon informs about press release
Stock NewsBIOCON18 Nov 2026
NULL
Biocon Receives European Approval Recommendation For Pertuzumab Biosimilar Pebrilzo
Stock NewsBIOCON18 Nov 2026
Biocon announced that its pertuzumab biosimilar Pebrilzo received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on 17 September 2026, recommending marketing authorisation in Europe. The medicine is intended for HER2-positive breast cancer and is comparable in quality, safety and efficacy to the reference product Perjeta.
Pebrilzo is a 420 mg/14 mL concentrate solution for infusion and is indicated for use with trastuzumab and chemotherapy in selected neoadjuvant and adjuvant treatment settings for adult patients with HER2-positive breast cancer. The development strengthens Biocon Biologics' oncology portfolio and expands its potential European market opportunity in biosimilar cancer therapies.
The approval recommendation is expected to support Biocon's global oncology franchise and may improve future revenue diversification, subject to final European Commission authorisation, commercial launch timing and market adoption. No specific financial impact, launch date, licensing economics or same-day share-price reaction was provided.
Biocon Receives US FDA Approval For Pebrilzo Breast Cancer Biosimilar
Stock NewsBIOCON16 Nov 2026
Biocon Limited has received US FDA approval for Pebrilzo, or pertuzumab-qcay, an injectable biosimilar to Perjeta. The monoclonal antibody is indicated for HER2-positive breast cancer and may be used with trastuzumab and chemotherapy in specified early-stage, metastatic, and neoadjuvant treatment settings.
The approval expands Biocon’s oncology biosimilar portfolio and marks its fifth cancer biosimilar cleared by the US FDA. Biocon has also entered into a global settlement and licence agreement with Genentech, which provides for the earliest licensed US launch of Pebrilzo in the third quarter of calendar year 2028. Commercialisation could support Biocon’s long-term oncology revenues and market presence, although the approval does not indicate immediate US sales.
Biocon shares traded higher by approximately 0.9% following the announcement. No acquisition, capital expenditure, dividend, or quantified earnings impact was disclosed.
Biocon gets USFDA’s nod for Pebrilzo
Stock NewsBIOCON16 Nov 2026
Pebrilzo is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells
Biocon informs about press release
Stock NewsBIOCON16 Nov 2026
NULL
Biocon Receives USFDA Approval For Pebrilzo Biosimilar To Perjeta
Stock NewsBIOCON16 Nov 2026
Biocon has received USFDA approval for Pebrilzo, or pertuzumab-qcay, a biosimilar to Roche's Perjeta used in combination with trastuzumab and docetaxel for eligible patients with HER2-positive breast cancer. The approval covers a 420 mg/14 mL intravenous single-dose vial formulation.[1][2]
Under its global settlement and licence agreement with Genentech, Biocon is scheduled to launch Pebrilzo in the US in the third quarter of CY 2028. The agreement also permits launches in the European Union and UK during the first quarter of CY 2027, subject to applicable regulatory approvals.[3][5]
The approval strengthens Biocon's oncology biosimilars portfolio and provides a defined pathway to enter the US pertuzumab market, although commercial revenue contribution is expected only after the planned launch. No financial quantum or immediate stock-price impact was provided in the available information.
Kotak Upgrades Biocon To Add With Rs 390 Target On Biosimilar Growth
Stock NewsBIOCON5 Nov 2026
Kotak Institutional Equities upgraded Biocon to Add and set a target price of Rs 390. Q2FY27 missed estimates because of deferred biosimilar shipments and slower generics growth, while management continues to expect a stronger second half supported by recent biosimilar launches.
Kotak expects biosimilars sales to deliver a 15% CAGR and EBITDA to grow at a 17% CAGR over FY26 to FY29. The estimates are supported by market share gains, new product launches, insulin capacity expansion, improving growth and debt reduction. The recent correction in Biocon’s share price has improved the risk-reward profile. The development is supportive for future earnings and leverage reduction, although near-term performance remains affected by shipment timing and slower generics growth.
Biocon Expects Stronger Second Half On New Biosimilar Launches
Stock NewsBIOCON4 Nov 2026
Biocon expects a stronger second half of FY27, supported by recent biosimilar launches, higher uptake of existing products and continued momentum across its biopharmaceutical portfolio. New products including Yesafili, an aflibercept biosimilar, and Kirsty, an insulin aspart biosimilar, are expected to contribute meaningfully to growth. The company also anticipates improved performance from interchangeable biosimilar insulins, aflibercept, bevacizumab, Fulphila and Ogivri. Increased insulin production and broader product traction could support revenue growth, improve capacity utilisation and strengthen Biocon’s position in diabetes and biosimilars. No specific revenue, EBITDA, production capacity or earnings guidance quantum was provided in the available update. Biocon’s NSE-listed equity closed at Rs 343.30 on 3rd November 2026, down 3.21%.
Biocon Reports Strong First Half FY27 Progress With Insulin Capacity Expansion
Stock NewsBIOCON4 Nov 2026
Biocon reported that achievements during the first half of FY27 have created a stronger base for performance in the second half. The company highlighted additional insulin production capacity, continued regulatory progress and business advancements across its biopharmaceutical operations.
During FY27, Biocon launched Bosaya, Aukelso, Yesafili and generic Liraglutide, while receiving European Medicines Agency approval for a new insulin fill finish plant in Malaysia. The facility is expected to unlock additional manufacturing capacity and support future insulin supply and commercial expansion.
The company reported Q2 FY27 total income of Rs 4,423 crores, EBITDA of Rs 865 crores and net profit of Rs 41 crores, with biopharma revenue growing 5%. The updates support potential improvement in revenue scale, market access and operating performance, although the announcement does not provide a specific production quantum or stock price reaction.
Biocon Reports Q2 Revenue Growth To Rs 4400 Crores
ResultBIOCON4 Nov 2026
Biocon reported Q2 revenue of Rs 4400 crores, compared with Rs 4295 crores in the corresponding quarter of the previous year, indicating 2.4 percent YoY growth. EBITDA, PAT, QoQ revenue, operating margin, net margin, and street expectations were not provided in the available information and are therefore not included.
The reported revenue performance reflects modest year-on-year growth for the quarter. No management guidance, detailed segment performance, or market reaction was available in the provided information.
Biocon Q2 Consolidated Net Profit Falls Below Estimates
ResultBIOCON4 Nov 2026
Biocon reported consolidated Q2 net profit of Rs 41.30 crores, declining from Rs 84.50 crores a year earlier. Profit was also below the estimate of Rs 165.00 crores, indicating a significant earnings miss. Revenue, EBITDA, operating margin, net margin, and sequential quarterly comparisons were not provided in the available information and are therefore excluded.
The weaker-than-expected consolidated profitability represents negative earnings news for Biocon. No management commentary, revised guidance, or additional operating details were available in the provided information. Biocon Limited is identified by ISIN INE376G01013.
Biocon Q2 EBITDA Declines Marginally, Margin Contracts Year On Year
ResultBIOCON4 Nov 2026
Biocon reported Q2 EBITDA of Rs 830 crores, compared with Rs 835 crores in the year-ago quarter, reflecting a decline of approximately 0.6% YoY. EBITDA margin stood at 18.9%, down from 19.45% YoY, indicating a 55 basis point contraction in operating profitability. Revenue, PAT and QoQ financial comparisons were not provided in the available update and are therefore not included. The result indicates broadly stable EBITDA with some pressure on operating margins. Biocon Limited is listed under the biotechnology and medical research sector, with NSE symbol BIOCON and ISIN INE376G01013.
Biocon reports Profit after tax of 91.70 Crores, in the September 2026 quarter
ResultBIOCON4 Nov 2026
NULL
Biocon Gains Global Approval For Yesintek Stelara Biosimilar
Stock NewsBIOCON26 Oct 2026
Biocon Biologics has secured approval for Yesintek, its ustekinumab biosimilar to Stelara, in additional global markets. Yesintek is approved for indications including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The product has received regulatory approval in the United States and Canada, while European approval was recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use. The approvals expand Biocon’s commercial reach in the global biosimilars market and may support future revenue growth and market share. No financial quantum, licensing income, earnings contribution or stock price reaction was provided in the available information.
Biocon Receives Earlier U.S. Launch Timeline For Pertuzumab Biosimilar Pebrilzo
Stock NewsBIOCON14 Oct 2026
Biocon announced an earlier launch timeline for Pebrilzo, its pertuzumab biosimilar, with commercial availability in the UNITED STATES expected in the third quarter of calendar year 2028. Pertuzumab is used with trastuzumab and chemotherapy for treating HER2-positive breast cancer.
The earlier launch date could accelerate Biocon Biologics’ entry into the U.S. pertuzumab market, supporting future biosimilars revenue and potentially strengthening its oncology portfolio. The update is a product-development and commercial-timeline milestone; the available information does not specify expected sales, pricing, regulatory conditions, or any immediate earnings impact.
Biocon Reports Rs 39.04 Crores NSE Block Trade Involving 1,057,554 Shares
Block DealBIOCON6 Oct 2026
Biocon recorded an NSE block trade involving approximately 1,057,554 shares at Rs 369.20 per share, representing a transaction value of about Rs 39.04 crores. The identities of the buyer and seller were not disclosed, and no information was provided on any change in promoter, institutional, or strategic investor ownership. The transaction price was below Biocon’s reported NSE price of Rs 370.70 on October 1, 2026, indicating a discount of approximately 0.4 percent. No post-deal stock price follow-through or additional market reaction was specified. Biocon Limited operates in the biopharmaceutical sector and trades under the NSE symbol BIOCON.
Biocon Malaysia Receives UK MHRA Approval For New Insulin Fill Finish Unit
Stock NewsBIOCON25 Sept 2026
Biocon Limited announced that its Malaysian manufacturing facility has received approval from the UK Medicines and Healthcare products Regulatory Agency for a new drug product fill finish unit for Semglee, an insulin glargine product. The approval follows clearance from the European Medicines Agency for the same fill finish line in July 2026.
The unit supports aseptic formulation, sterile packaging, and final delivery preparation of insulin products. The regulatory approval strengthens Biocon’s manufacturing and supply chain capabilities for insulin products serving regulated markets in the UK and Europe. No investment amount, production capacity, revenue contribution, or earnings guidance was disclosed in the announcement.
Biocon gains EMA CHMP nod for first tailored-pathway pertuzumab biosimilar
Stock NewsBIOCON21 Sept 2026
Biocon has announced that its pertuzumab biosimilar has become the first biosimilar to receive a positive approval recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) using a new customised clinical assessment method. This tailored approach reduces the need for extensive comparative efficacy trials where the molecule can be robustly characterised analytically, potentially shortening development timelines and lowering overall clinical trial costs for this and future biosimilars. The recommendation is an important regulatory milestone for Biocon’s biologics franchise, reinforcing its position in the global biosimilars market and specifically in oncology, given pertuzumab’s use in the treatment of HER2-positive breast cancer in adults. While exact revenue guidance or market share projections linked to this product are not disclosed, successful conversion of the CHMP opinion into a final European marketing authorisation would open access to key EU markets where the reference product has meaningful penetration and pricing is relatively attractive, supporting Biocon’s medium-term growth visibility in its biosimilars vertical. The use of the customised clinical method may also create a strategic template for Biocon’s pipeline, allowing more efficient allocation of R&D capital and potentially improving returns on invested capital over time. From an Indian market perspective, the development is corporate in nature rather than a domestic macro event, but it is incrementally positive for earnings prospects from export markets and may be watched closely by investors tracking Biocon’s international biosimilars strategy and its ability to monetise complex oncology products globally.

